TOCAGEN INC’s (NASDAQ:TOCA) lock-up period will end on Tuesday, October 10th. TOCAGEN INC had issued 8,500,000 shares in its public offering on April 13th. The total size of the offering was $85,000,000 based on an initial share price of $10.00. After the expiration of TOCAGEN INC’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

A number of research firms have recently weighed in on TOCA. Zacks Investment Research raised TOCAGEN INC from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $24.00 price target on shares of TOCAGEN INC in a research note on Tuesday, July 25th.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/tocagen-incs-lock-up-period-to-end-on-october-10th-nasdaqtoca/1613954.html.

Shares of TOCAGEN INC (TOCA) opened at 10.44 on Friday. The stock has a market cap of $206.81 million and a price-to-earnings ratio of 2.13. TOCAGEN INC has a 52 week low of $9.68 and a 52 week high of $17.95. The company has a 50-day moving average price of $12.69 and a 200-day moving average price of $13.25.

TOCAGEN INC (NASDAQ:TOCA) last released its earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. Equities analysts anticipate that TOCAGEN INC will post ($2.51) EPS for the current year.

A number of institutional investors have recently made changes to their positions in TOCA. TD Asset Management Inc. bought a new position in TOCAGEN INC in the 2nd quarter valued at $158,000. Schwab Charles Investment Management Inc. bought a new position in TOCAGEN INC in the 2nd quarter valued at $165,000. Alps Advisors Inc. bought a new position in TOCAGEN INC in the 2nd quarter valued at $215,000. Bank of New York Mellon Corp bought a new position in TOCAGEN INC in the 2nd quarter valued at $281,000. Finally, Victory Capital Management Inc. bought a new position in TOCAGEN INC in the 2nd quarter valued at $837,000. 37.87% of the stock is currently owned by institutional investors.

About TOCAGEN INC

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Receive News & Ratings for TOCAGEN INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TOCAGEN INC and related companies with Analyst Ratings Network's FREE daily email newsletter.